製品番号: HY-N0060

Ferulic acid

(別名: Coniferic acid)

17 Cited Publications

カスタマーレビュー

Based on 17 publication(s) in Google Scholar

Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.97%
CAS 番号: 1135-24-6
分子式: C₁₀H₁₀O₄
分子量:194.19

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ferulic acid 構造式

CAS 番号: 1135-24-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (17)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

IC₅₀ & Target^[1]

FGFR1

3.78 μM (IC₅₀)

FGFR2

12.5 μM (IC₅₀)

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
A549	IC₅₀	2.6 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay	[PMID: 27162124]
A549	IC₅₀	3.1 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27162124]
A549	IC₅₀	3.2 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay	[PMID: 27162124]
A549	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 27700070]
BT-549	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 27700070]
BT-549	IC₅₀	1.2 μM Compound: 1	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
BV-2	IC₅₀	>50 μM Compound: 7	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27700070]
BV-2	EC₅₀	>10 μM Compound: 2	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay	[PMID: 29407994]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27290693]
HT-22	EC₅₀	>10 μM Compound: 2	Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay	[PMID: 29407994]
K562	IC₅₀	>1000 μM Compound: Ferulic acid	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
LoVo	IC₅₀	95 μM Compound: 13	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF7	IC₅₀	0.36 μM Compound: FerA	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.5 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
MDA-MB-231	IC₅₀	15 μM Compound: FerA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MT4	CC₅₀	>10 μM Compound: 8	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay	[PMID: 26756779]
MT4	EC₅₀	>10 μM Compound: 8	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay	[PMID: 26756779]
Neutrophil	IC₅₀	200 μM Compound: 2; FA	Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay	[PMID: 27290693]
PC-3	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
Platelet	IC₅₀	2.7 mM Compound: Ferulic acid	Inhibition of ADP-induced rabbit platelet aggregation compound pre-incubated in rabbit liver microsomal suspension Inhibition of ADP-induced rabbit platelet aggregation compound pre-incubated in rabbit liver microsomal suspension	[PMID: 23466230]
Platelet	IC₅₀	19.58 mM Compound: Ferulic acid	Antiplatelet aggregation activity in rabbit platelet assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in rabbit platelet assessed as reduction in ADP-induced platelet aggregation	[PMID: 34902735]
RAW264.7	IC₅₀	>100 μM Compound: 12	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
SH-SY5Y	IC₅₀	11.82 μM Compound: ferulic acid	Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay	[PMID: 28282613]
SK-MEL-2	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 27700070]
SK-MEL-28	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-OV-3	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 27700070]
TT	IC₅₀	150 μM Compound: Ferulic acid	Cytotoxicity against human TT cells by trypan blue dye-based assay Cytotoxicity against human TT cells by trypan blue dye-based assay	[PMID: 31336310]
U-373MG ATCC	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27290693]

体外実験

Ferulic acid (FA) is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. Ferulic acid exhibits great inhibitory activity on FGFR1 with an inhibitory rate of 92% at 1 μM. The proliferation of HUVEC stimulated by FGF1 is markedly decreased after Ferulic acid treatment ranging from 5 to 40 μM for 24 h. Ferulic acid does not exert significant cell viability up to 20 μM, but over 30 μM Ferulic acid exhibits a cytotoxic effect in HUVEC compare to the control. Ferulic acid inhibits FGF1-induced HUVEC migration and invasion in a dose-dependent manner. Ferulic acid markedly suppresses the FGF1-induced phosphorylation of PI3K and Akt. Ferulic acid treatments significantly inhibit MMP-2 and MMP-9 expression stimulated by FGF1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Treatment with Ferulic acid (FA) potently inhibits FGF1-induced neovascularization. It is found that intragastric administration of Ferulic acid markedly inhibits tumor volume and tumor weight, as compare to the counterparts treated with DMSO. Furthermore, Ferulic acid treatment is well tolerated, and there is no significant difference in weight between the vehicle group and the FA-treated groups^[1]. Ferulic acid (0.01, 0.1, 1 or 10 mg/kg) given by oral route decreases significantly the immobility time in the forced swimming test (FST) and tail suspension test (TST), whereas produces no effect in the open-field test. Results demonstrate that the administration of Ferulic acid (0.001 mg/kg, p.o.) boosts the antidepressant-like effect of Fluoxetine (HY-B0102) (5 mg/kg, p.o.) in the TST^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 1135-24-6
性状 Solid
分子量 194.19
分子式 C₁₀H₁₀O₄
Color Off-white to yellow
SMILES

O=C(O)/C=C/C1=CC=C(O)C(OC)=C1
別名

Coniferic acid
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Monophenols
Initial Source
- Plants
- other families
- Endogenous metabolite
- Human Gut Microbiota Metabolites
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (17)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayHistological Imaging/StainingWBELISAIF

Sort by:

Journal Impact Factor

Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
Phytomedicine

Bioactive equivalent combinatorial components of Xiao-Xu-Ming decoction inhibit the calmodulin-mediated MLCK/MLC axis to attenuate coronary artery spasm. [Abstract]

2025 Jul:142:156713. PMID: 40349422
Phytomedicine

Herbal-based Xuebijing injection ameliorated vascular endothelial dysfunction via inhibiting ACLY/MYB/RIG-I axis in sepsis-associated lung injury. [Abstract]

2025 May:140:156573. PMID: 40088739

Ferulic acid purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156573. [Abstract]

HPLC chromatogram of Ferulic Acid.

Ferulic acid purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156573. [Abstract]

Ferulic Acid (FA, 100 μM; 4 h) effectively inhibited LPS-induced upregulation of E-selectin, VCAM-1, TF and PAI-1 in HUVEC.
Free Radic Biol Med

Ferulic acid attenuates Sarcopenia progression by inhibiting peroxisomal ACOX1. [Abstract]

2025 Aug 13:240:183-196. PMID: 40816648

Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]

Effects of different concentrations of Ferulic acid (FA, 10, 50, 200, 500 μg/mL) and/or Dex (20 μM) continuously treated for 48 h on the proliferative vigor of C2C12 cells (CCK-8 assay). The results showed that compared with dexamethasone (Dex) treatment, FA (1–50 μg/mL; 48 h) treatment tended to promote the proliferative activity of C2C12 cells. Furthermore, FA (50 μg/mL) significantly reversed the decrease in proliferative activity of C2C12 cells induced by Dex treatment.

Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]

Myotube(dark blue) morphology of each group after 72 h of treatment with Gimsa staining. Gimsa staining showed that the diameter and number of myotube decreased after Dexamethasone (Dex) treatment and recovered after Ferulic acid (FA, 10-200 μg/mL; 72 h) intervention.

Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]

Effects of different concentrations of Ferulic acid (FA,10, 50, 200 μg/ml) and/or Dexamethasone (Dex, 20 μM) on the levels of inflammatory factors TNF-α, IL-6 in the supernatant of C2C12 cell culture after 72 h of continuous treatment. The results showed that FA (10–200 μg/mL) could reduce the levels of TNF-α and IL-6 in the Dex group, with the effects being more significant at concentrations of 50 μg/mL and 200 μg/mL, indicating that FA inhibits sarcopenia-associated inflammation.

Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]

Immunofluorescence technique was used to detect the expression of ACOX1 at different concentrations of Ferulic acid (FA) (50, 200 μg/ml) and/or Dexamethasone (Dex) (20 μM) after 72 h of continuous treatment (200 × ). NC: Normal Control group; Dex: Model group; FA: Model + FA group. Immunofluorescence assay showed that ACOX1 was significantly reduced after Ferulic acid (FA) (200 μg/mL) intervention compared with the Dex group.
Neurotherapeutics

Ferulic Acid Improves Synaptic Plasticity and Cognitive Impairments by Alleviating the PP2B/DARPP-32/PP1 Axis-Mediated STEP Increase and Aβ Burden in Alzheimer's Disease. [Abstract]

2023 Jul;20(4):1081-1108. PMID: 37079191

Ferulic acid purchased from MedChemExpress. Usage Cited in: Neurotherapeutics. 2023 Jul;20(4):1081-1108. [Abstract]

Ferulic acid (FA; 5, 10 μM; 2 h) restores the Aβ-induced decreased expression of p-Y416 and increased expression of npS221 in neuronal cells.
Arab J Chem

2024 Aug.
CNS Neurosci Ther

Tongqiao Huoxue Decoction ameliorates traumatic brain injury-induced gastrointestinal dysfunction by regulating CD36/15-LO/NR4A1 signaling, which fails when CD36 and CX3CR1 are deficient. [Abstract]

2023 Jun;29 Suppl 1(Suppl 1):161-184. PMID: 37157929
Pharmaceuticals (Basel)

Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay. [Abstract]

2022 Jan 31;15(2):179. PMID: 35215292
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Biomedicines

Ferulic Acid Alleviates Chemotherapy-Induced POI by Targeting the Grp78 and Perk-eIF2α-ATF4-CHOP Pathway to Attenuate Endoplasmic Reticulum Stress. [Abstract]

2026 Mar 19;14(3):714. PMID: 41898358
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
Brain Res Bull

Ferulic acid promotes proliferation and angiogenesis of cerebral microvascular endothelial cells in Moyamoya disease via the SIRT1/HIF-1α/VEGF-A axis. [Abstract]

2026 Jun 1:239:111886. PMID: 41980628
Stem Cells Int

Ferulic Acid Alleviates Inflammation and Promotes Osteogenic Differentiation in Periodontitis by Inhibiting NF- κ B Pathway. [Abstract]

2025 Dec 17:2025:1891956. PMID: 41497811
J Bioenerg Biomembr

Ferulic acid relieves hypoxic damage by inhibiting endoplasmic reticulum stress, oxidative stress, and apoptosis through activating FOXA2-modulated Nrf2/HO-1 pathway in spermatogonial cells. [Abstract]

2026 Mar 24;58(1):4. PMID: 41874733
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Appl Bionics Biomech

Ferulic Acid Protects Endothelial Cells from Hypoxia-Induced Injury by Regulating MicroRNA-92a. [Abstract]

2022 Jul 31:2022:6148361. PMID: 35959508
Research Square Preprint

2024 Dec 17.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (514.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1496 mL

25.7480 mL

51.4960 mL

5 mM

1.0299 mL

5.1496 mL

10.2992 mL

10 mM

0.5150 mL

2.5748 mL

5.1496 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[1]

HUVEC (5×10⁴ cells/well) are plated onto a gelatinized 24-well culture plate and cultured in ECGS containing 15% FBS. HUVEC are treated with DMSO (0.1%) or different concentrations of Ferulic acid (FA) (0, 2.5, 5, 10, 20, 30, 40 μM) for 24 h. Cell viability is determined by the MTT assay. After 4 h of incubation, the absorbance is measured at 450 nm with a microplate reader. The results are calculated from six replicates of each experiment. Three independent experiments are performed^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Male Swiss mice (30 to 40 g) are maintained at 21 to 23°C with free access to water and food, under a 12:12 h light/dark cycle (lights on at 07:00 h). All manipulations are carried out between, 9:00 and 16:00 h, with each animal used only once. In order to investigate the antidepressant-like effect of Ferulic acid, Ferulic acid is administered at a dose range of 0.001 to 10 mg/kg, by oral route (p.o.) 60 min before the forced swimming test (FST), tail suspension test (TST) or open-field test. The control animals receive appropriate vehicle^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31. [Content Brief]

[2]. Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.1496 mL	25.7480 mL	51.4960 mL	128.7399 mL
	5 mM	1.0299 mL	5.1496 mL	10.2992 mL	25.7480 mL
	10 mM	0.5150 mL	2.5748 mL	5.1496 mL	12.8740 mL
	15 mM	0.3433 mL	1.7165 mL	3.4331 mL	8.5827 mL
	20 mM	0.2575 mL	1.2874 mL	2.5748 mL	6.4370 mL
	25 mM	0.2060 mL	1.0299 mL	2.0598 mL	5.1496 mL
	30 mM	0.1717 mL	0.8583 mL	1.7165 mL	4.2913 mL
	40 mM	0.1287 mL	0.6437 mL	1.2874 mL	3.2185 mL
	50 mM	0.1030 mL	0.5150 mL	1.0299 mL	2.5748 mL
	60 mM	0.0858 mL	0.4291 mL	0.8583 mL	2.1457 mL
	80 mM	0.0644 mL	0.3218 mL	0.6437 mL	1.6092 mL
	100 mM	0.0515 mL	0.2575 mL	0.5150 mL	1.2874 mL

Keywords

Ferulic acid

17 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Ferulic acid

Anti-Infection Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Phenols Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Food Additive Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Ferulic acid

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (17)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献